ChromaDex Corporation - Common Stock (CDXC)

Frequently Asked Questions About ChromaDex Corporation - Common Stock (CDXC)

Does ChromaDex conduct its own research?

Yes, ChromaDex conducts its own research and development as part of its commitment to innovation in the health and wellness space. The company has a dedicated team of scientists and researchers who focus on exploring new applications for its existing ingredients, developing new products, and conducting clinical trials to further substantiate the health benefits of its formulations.

Has ChromaDex been involved in any controversies?

ChromaDex has faced scrutiny in the past regarding the efficacy and marketing of its products. However, the company has worked to address concerns through enhanced transparency and by backing its products with clinical research. As with any health-related company, transparency, scientific validation, and adherence to regulatory standards play key roles in maintaining consumer trust.

How can investors stay informed about ChromaDex?

Investors can stay informed about ChromaDex by regularly checking its official website, where the company publishes financial reports, press releases, and updates about product launches and partnerships. Additionally, following ChromaDex on financial news platforms and subscribing to investor newsletters can provide timely information regarding company performance and market initiatives.

How does ChromaDex ensure product quality?

ChromaDex adheres to stringent quality control standards throughout its manufacturing and production processes. The company employs Good Manufacturing Practices (GMP) to ensure the integrity, safety, and effectiveness of its products. Additionally, ChromaDex conducts regular testing of its ingredients and finished products to guarantee they meet or exceed industry standards.

How is ChromaDex addressing sustainability?

ChromaDex is committed to sustainability in its operations and product sourcing. The company actively seeks to minimize its environmental impact by implementing eco-friendly practices in manufacturing and packaging. Additionally, ChromaDex focuses on sourcing raw materials responsibly, ensuring they are produced with minimal environmental disruption.

Is ChromaDex a publicly traded company?

Yes, ChromaDex Corporation is publicly traded on the NASDAQ stock exchange under the ticker symbol 'CDXC'. Being a publicly traded company allows ChromaDex to raise capital through the sale of shares, which is crucial for funding its ongoing research and development projects.

What are some products offered by ChromaDex?

ChromaDex offers a range of products, with its most notable being its proprietary Nicotinamide Riboside (NR) supplements, which are marketed under the brand name Elysium Basis. In addition to NR, ChromaDex also provides a variety of other ingredients that support health and wellness, such as those focusing on skin health, gut health, and general cellular function.

What are the competitive advantages of ChromaDex?

ChromaDex's competitive advantages include its strong intellectual property portfolio, with several patents protecting its proprietary ingredients like NR. Additionally, the company's commitment to scientific research and high-quality manufacturing practices differentiates it from competitors. ChromaDex's established reputation in the health and wellness market further enhances its appeal to consumers and industry partners.

What does ChromaDex Corporation do?

ChromaDex Corporation is a biotechnology company focused on delivering innovative products and services in the health and wellness sector. The company specializes in the research, development, and commercialization of ingredients that promote healthy aging and enhance cellular health. Its flagship product, nicotinamide riboside (NR), is a form of vitamin B3 that has been shown to support cellular metabolism and increase levels of NAD+, a critical coenzyme in the body.

What financial performance has ChromaDex exhibited?

ChromaDex has shown varying financial performance since becoming a publicly traded company. Key indicators include revenue growth owing to increased demand for its NR products and its expanding presence in the dietary supplement market. However, it’s important for investors to review regular financial statements and reports to assess current performance and growth trajectories.

What is NICOTINAMIDE RIBOSIDE (NR)?

Nicotinamide riboside (NR) is a novel form of vitamin B3 that has gained significant attention for its potential health benefits. It serves as a precursor to NAD+ (nicotinamide adenine dinucleotide), a coenzyme essential for cellular energy metabolism and proper functioning of various biological processes. Research suggests that NR supplementation may help improve metabolic health, enhance cognitive function, and potentially promote longevity.

What is the future outlook for ChromaDex?

The future outlook for ChromaDex appears promising, as the demand for health and wellness products continues to grow. With a focus on innovation, scientific research, and expanding its product lineup, ChromaDex is well-positioned to capitalize on trends related to healthy aging and metabolic health. Investors and consumers alike are encouraged to follow the company's developments closely to understand its evolving role in the market.

What is the scientific research behind ChromaDex's products?

ChromaDex invests heavily in scientific research and clinical trials to validate the efficacy of its products. The company collaborates with academic institutions and conducts studies that demonstrate the health benefits of its ingredients, particularly NR. Many of these studies are published in esteemed scientific journals, adding credibility to their claims and promoting consumer trust.

What is the significance of NAD+ in human health?

NAD+ (nicotinamide adenine dinucleotide) is a crucial coenzyme found in all living cells, playing a vital role in metabolism, energy production, and DNA repair. As individuals age, NAD+ levels decline, which is associated with various age-related health issues. Maintaining adequate levels of NAD+ through supplementation, such as with Nicotinamide Riboside, may contribute to promoting longevity, enhancing cellular health, and improving overall well-being.

What is the target demographic for ChromaDex's products?

ChromaDex's products primarily target health-conscious consumers, particularly those interested in anti-aging solutions, metabolic health, and overall wellness. This includes consumers of varying ages who are increasingly concerned about maintaining their health and vitality as they age, making them receptive to products that can support healthy aging.

What markets does ChromaDex target?

ChromaDex primarily targets the dietary supplement, functional food, and beverage markets. Its products are aimed at health-conscious consumers interested in obtaining high-quality, scientifically-backed ingredients that support overall well-being, healthy aging, and improved metabolic health.

What partnerships has ChromaDex established?

ChromaDex has established various partnerships with leading companies in the dietary supplement and nutraceutical industries, including strategic collaborations for product development, distribution, and marketing. These partnerships enhance ChromaDex's ability to reach a broader audience and provide its innovative products to consumers worldwide.

What regulatory bodies oversee ChromaDex?

ChromaDex is overseen by various regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC). These organizations set guidelines and regulations for dietary supplements and health claims. Compliance with these regulations is crucial for ChromaDex to ensure product safety, efficacy, and marketing practices are aligned with industry standards.

Where is ChromaDex Corporation based?

ChromaDex Corporation is headquartered in Los Angeles, California. This strategic location places the company in the heart of one of the largest and most dynamic markets for biotech and health innovation, allowing it to collaborate with various research institutions and develop partnerships within the industry.

What is the current price of ChromaDex Corporation - Common Stock?

The current price of ChromaDex Corporation - Common Stock is 7.870

When was ChromaDex Corporation - Common Stock last traded?

The last trade of ChromaDex Corporation - Common Stock was at 4:00 pm EDT on March 18th, 2025

What is the market capitalization of ChromaDex Corporation - Common Stock?

The market capitalization of ChromaDex Corporation - Common Stock is 536.71M

How many shares of ChromaDex Corporation - Common Stock are outstanding?

ChromaDex Corporation - Common Stock has 68.20M shares outstanding.